Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
New

A Study of MGC030 in Participants With Advanced Solid Tumors

for
Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer,
Location: Lake Success NY
Sponsor: MacroGenics

Sex: All

Age: 18+

Code: NCT07822399

Phase 1, Recruiting

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

for
Advanced Pancreatic Ductal Adenocarcinoma,
Location: Pittsburgh PA
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07619521

Phase 1, Phase 2, Recruiting

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

for
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer,
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06483555

Phase 1, Phase 2, Recruiting

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

for
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation,
Location: New York NY
Sponsor: General Oncology, Inc.

Sex: All

Age: 18+

Code: NCT04150042

Phase 1, Recruiting

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas,
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18 - 70+

Code: NCT03977233

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer

for
Pancreas Cancer, Pancreatic Cancer,
Location: Camden NJ
Sponsor: The Cooper Health System

Sex: All

Age: 18+

Code: NCT02707315

Early Phase 1, Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

for
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer,
Location: Fairfax VA, Denver CO, Sarasota FL, Nashville TN,
Sponsor: ArriVent BioPharma, Inc.

Sex: All

Age: 18+

Code: NCT07066657

Phase 1, Recruiting

Autologous CAR-T Cells Targeting B7-H3 in PDAC

for
Pancreas Cancer, Relapse, Resistant Cancer
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06158139

Phase 1, Recruiting

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

for
Tumor, Solid, Pancreatic Cancer, Melanoma
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18 - 70+

Code: NCT03454035

Phase 1, Recruiting

A Study of MGC028 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma,
Location: Boston MA, New York NY, Grand Rapids MI, San Antonio TX,
Sponsor: MacroGenics

Sex: All

Age: 18+

Code: NCT06723236

Phase 1, Recruiting
Active & Responsive

A Study of YL201 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Boston MA, New York NY, Washington D.C. DC, Fairfax VA,
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Sex: All

Age: 18+

Code: NCT05434234

Phase 1, Phase 2, Recruiting

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

for
Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer,
Location: Dallas TX
Sponsor: Blue Earth Diagnostics

Sex: All

Age: 18 - 70+

Code: NCT07432633

Phase 1, Phase 2, Recruiting

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: New York NY, Philadelphia PA, Jacksonville FL,
Sponsor: BicycleTx Limited

Sex: All

Age: 18+

Code: NCT07450859

Phase 2, Recruiting

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

for
Foregut Adenocarcinoma, Esophageal Adenocarcinoma,
Location: New Haven CT
Sponsor: Yale University

Sex: All

Age: 18 - 70+

Code: NCT07282912

Phase 2, Recruiting

Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

for
Adenocarcinoma of the Pancreas
Location: San Antonio TX
Sponsor: The University of Texas Health Science Center at San Antonio

Sex: All

Age: 0+

Code: NCT07340151

Recruiting

PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

for
PDAC - Pancreatic Ductal Adenocarcinoma
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT07047807

Recruiting

Nutrition Intervention for Pancreatic Cancer

for
Pancreatic Ductal Adenocarcinoma (PDAC),
Location: Philadelphia PA
Sponsor: Children's Hospital of Philadelphia

Sex: All

Age: 18+

Code: NCT07554560

Recruiting

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

for
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer,
Location: Gainesville FL
Sponsor: University of Florida

Sex: All

Age: 18 - 70+

Code: NCT05000294

Phase 1, Phase 2, Recruiting

Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms

for
Pancreatic Cystic Neoplasm
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT07529483

Phase 2, Recruiting

MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer

for
Pancreatic Adenocarcinoma
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT07619391

Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial